Literature DB >> 1864532

Maintenance treatment of duodenal ulceration: ranitidine 300 mg at night is better than 150 mg in cigarette smokers.

F I Lee1, M Hardman, M E Jaderberg.   

Abstract

Two hundred patients received either ranitidine 150 mg or 300 mg at night for 18 months to prevent duodenal ulcer relapse. Recurrence rates were lower in patients receiving the higher dose of ranitidine (3.1% v 9.7%, p = 0.78; 6.5% v 16.7%, p = 0.037; and 8.9% v 17.0%, p = 0.121 at six, 12, and 18 months respectively). In patients receiving ranitidine 150 mg, recurrences were significantly more common in smokers than non-smokers after 12 and 18 months, while in patients receiving ranitidine 300 mg recurrence rates were similar in smokers and non-smokers. Ranitidine 300 mg at night abolishes the adverse effect of smoking observed during maintenance treatment with ranitidine 150 mg at night and may therefore be an appropriate maintenance dose for smokers who relapse during standard dose maintenance treatment.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1864532      PMCID: PMC1378797          DOI: 10.1136/gut.32.2.151

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  The effects of cigarette smoking on plasma concentrations of gastric antisecretory drugs.

Authors:  E J Boyd; D A Johnston; K G Wormsley; W N Jenner; X Salanson
Journal:  Aliment Pharmacol Ther       Date:  1987-02       Impact factor: 8.171

Review 2.  Comparison of ranitidine and cimetidine ulcer maintenance therapy.

Authors:  J H Kurata; G G Koch; A N Nogawa
Journal:  J Clin Gastroenterol       Date:  1987-12       Impact factor: 3.062

3.  Comparison of tri-potassium di-citrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers.

Authors:  F I Lee; I M Samloff; M Hardman
Journal:  Lancet       Date:  1985-06-08       Impact factor: 79.321

4.  Ranitidine: prophylaxis of duodenal ulcer recurrence.

Authors:  F I Lee; J D Fielding; G K Holmes; K R Hine; J A Gibson; E Lochee-Bayne; C Mackay; K G Mitchell; W R Pickard; R T Orchard
Journal:  Hepatogastroenterology       Date:  1984-04

5.  Ranitidine and cimetidine in prevention of duodenal ulcer relapse. A double-blind, randomised, multicentre, comparative trial.

Authors:  K R Gough; M G Korman; K D Bardhan; F I Lee; J P Crowe; P I Reed; R N Smith
Journal:  Lancet       Date:  1984-09-22       Impact factor: 79.321

6.  Recurrence of duodenal ulcer after medical treatment.

Authors:  M R Lane; S P Lee
Journal:  Lancet       Date:  1988-05-21       Impact factor: 79.321

7.  Model of medical treatment for duodenal ulcer.

Authors:  R E Pounder
Journal:  Lancet       Date:  1981-01-03       Impact factor: 79.321

8.  Cimetidine treatment for the prevention of recurrence of duodenal ulcer: an international collaborative study.

Authors:  W L Burland; B W Hawkins; J Beresford
Journal:  Postgrad Med J       Date:  1980-03       Impact factor: 2.401

9.  Maintenance therapy of duodenal ulcer with famotidine. A multicenter United States study.

Authors:  E C Texter; F Navab; G Mantell; R Berman
Journal:  Am J Med       Date:  1986-10-24       Impact factor: 4.965

  9 in total
  3 in total

Review 1.  Clinical pharmacology and therapeutics.

Authors:  R C Horton; M J Kendall
Journal:  Postgrad Med J       Date:  1991-12       Impact factor: 2.401

Review 2.  Treatment of peptic ulcer in the elderly. Proton pump inhibitors and histamine H2 receptor antagonists.

Authors:  M Lazzaroni; G Bianchi Porro
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 3.  Prescribing policy for antiulcer treatment in the elderly.

Authors:  G Bianchi Porro; M Lazzaroni
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.